<DOC>
	<DOCNO>NCT01653314</DOCNO>
	<brief_summary>The purpose Study Assess Safety Pharmacokinetics megavec 400 mg ( Imatinib mesylate ) Fasted Conditions Healthy Male Subjects .</brief_summary>
	<brief_title>Megavec 400 mg ( Imatinib Mesylate ) Healthy Adult Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Healthy male subject age 20 55 year The subject Body weight ≥55 kg ideal body weight ( IBW ) within ±20 % A Subject judge healthy investigator participate study base screen result ( accord standard reference index update recently ) A subject provide write informed consent participate study cooperative regard compliance study relate constraint . A subject sign symptom previously diagnose disease respiratory , cardiovascular , endocrinology , liver , kidney , hematology , neurology psychology function significant diseases history Known allergy hypersensitivity study medication AST ALT great 1.25 time upper limit reference range Total bilirubin great 1.25 time upper limit reference range base screen result A subject judge ineligible investigator participate study reason contain clinical laboratory test</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>